系统性Piezo1激活可以改善阿尔茨海默氏症患者的脑血管功能
Zeynab Tabrizi1, Xin Rui Lim2, Supriya Chakraborty1
1Department of Biology, University of Miami, Miami, Florida, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 16, 2025
概括
在阿尔茨海默病小鼠模型中,Piezo1的系统激活改善了脑血流和功能性高血压. 这表明Piezo1是阿尔茨海默病早期脑血管功能障碍的潜在治疗标.
科学领域:
- 神经科学是一个神经科学.
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 的特点是脑血流 (CBF) 减少和功能性高血压 (FH) 受损.
- 这些脑血管缺陷是早期的特征,有助于AD进展.
研究的目的:
- 调查系统性Piezo1激活对AD小鼠模型中脑血管缺陷的影响.
- 确定是否针对机械敏感离子通道Piezo1可以改善与AD相关的血管功能障碍.
主要方法:
- 在AD的5xFAD小鼠模型中利用了两光子体内成像和激光光斑成像.
- 评估CBF,毛细血管停滞和FH在对胡须刺激的反应中.
- 系统地使用Piezo1激动剂Yoda1.
主要成果:
- 与野生类型对照组相比,5xFAD小鼠表现出增加的毛细血管停滞和减少的CBF和FH.
- Yoda1的使用显著减少了大约65%的毛细血管位.
- 在5xFAD小鼠中,Yoda1治疗增加了CBF和改善了FH,恢复了对照水平的反应.
结论:
- 在AD的背景下,Piezo1激活增强了微血管流和神经血管合.
- 在阿尔茨海默病中,Piezo1代表了解决早期脑血管功能障碍的有希望的治疗标.
相关概念视频
01:22Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K